JP2008510723A - 血管新生の治療法 - Google Patents

血管新生の治療法 Download PDF

Info

Publication number
JP2008510723A
JP2008510723A JP2007528076A JP2007528076A JP2008510723A JP 2008510723 A JP2008510723 A JP 2008510723A JP 2007528076 A JP2007528076 A JP 2007528076A JP 2007528076 A JP2007528076 A JP 2007528076A JP 2008510723 A JP2008510723 A JP 2008510723A
Authority
JP
Japan
Prior art keywords
vegf
laccer
angiogenesis
pecam
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007528076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510723A5 (de
Inventor
チャタジー スブロト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2008510723A publication Critical patent/JP2008510723A/ja
Publication of JP2008510723A5 publication Critical patent/JP2008510723A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Textile Engineering (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007528076A 2004-08-20 2005-08-19 血管新生の治療法 Pending JP2008510723A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60301604P 2004-08-20 2004-08-20
PCT/US2005/029730 WO2006023827A2 (en) 2004-08-20 2005-08-19 Methods for treatment of angiogenesis

Publications (2)

Publication Number Publication Date
JP2008510723A true JP2008510723A (ja) 2008-04-10
JP2008510723A5 JP2008510723A5 (de) 2008-10-16

Family

ID=35968249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528076A Pending JP2008510723A (ja) 2004-08-20 2005-08-19 血管新生の治療法

Country Status (9)

Country Link
US (1) US20090202439A1 (de)
EP (1) EP1799258A4 (de)
JP (1) JP2008510723A (de)
KR (1) KR20070085232A (de)
CN (1) CN101123879A (de)
AU (1) AU2005277186A1 (de)
CA (1) CA2581173A1 (de)
RU (1) RU2007110847A (de)
WO (1) WO2006023827A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1811991B1 (de) * 2004-11-10 2018-11-07 Genzyme Corporation Behandlung von Typ 2 Diabetes mit Inhibitoren der Glycosphigolipid-Synthese
EP2992902A1 (de) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Mit peg beschichtete lipid-komplexe und ihre anwendung
CA2649020A1 (en) * 2006-04-20 2007-11-01 Silence Therapeutics Ag Means for inhibiting the expression of cd31
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
EP2167485B1 (de) 2007-05-31 2015-09-30 Genzyme Corporation Glucosylceramidsynthaseinhibitoren vom 2-acylaminopropoanoltyp
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
EP2320886B1 (de) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramid-synthase-hemmung zur behandlung von kollabierender glomerulopathie und anderen glomerulären erkrankungen
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
WO2012055814A1 (en) * 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv
US20170119683A1 (en) * 2014-04-28 2017-05-04 The Johns Hopkins University Biopolymer-encapsulated glycosyl transferase inhibitor compositions and methods for treating diabetes and cardiac indications
CN107502623B (zh) * 2016-06-13 2021-06-08 首都医科大学 递送VEGF-siRNA的纳米金刚石,其制备,活性和应用
CA3225489A1 (en) * 2021-08-10 2023-02-16 The Johns Hopkins University Compositions and methods for treatment of cancer
CN115707472A (zh) * 2021-08-19 2023-02-21 中国科学院苏州纳米技术与纳米仿生研究所 C16 Laccer在制备修复脊髓损伤的药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01254623A (ja) * 1988-04-04 1989-10-11 Univ Michigan スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬
JP2002521435A (ja) * 1998-07-27 2002-07-16 ジョンズ・ホプキンス・ユニバーシティ ラクトシルセラミドによって調節される病態を治療する方法
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド ｅＮＯＳ活性の調節とその治療的使用
WO2003082360A1 (en) * 2002-03-29 2003-10-09 Boston Scientific Limited Drug delivery particle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01254623A (ja) * 1988-04-04 1989-10-11 Univ Michigan スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬
JP2002521435A (ja) * 1998-07-27 2002-07-16 ジョンズ・ホプキンス・ユニバーシティ ラクトシルセラミドによって調節される病態を治療する方法
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド ｅＮＯＳ活性の調節とその治療的使用
WO2003082360A1 (en) * 2002-03-29 2003-10-09 Boston Scientific Limited Drug delivery particle

Also Published As

Publication number Publication date
CN101123879A (zh) 2008-02-13
AU2005277186A1 (en) 2006-03-02
KR20070085232A (ko) 2007-08-27
RU2007110847A (ru) 2008-09-27
WO2006023827A3 (en) 2007-10-25
CA2581173A1 (en) 2006-03-02
US20090202439A1 (en) 2009-08-13
EP1799258A4 (de) 2009-07-22
EP1799258A2 (de) 2007-06-27
WO2006023827A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
JP2008510723A (ja) 血管新生の治療法
Liu et al. Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis
Weston et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Barile et al. The RAGE axis in early diabetic retinopathy
US9982265B2 (en) Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
JP4863548B2 (ja) 結合組織増殖因子のモジュレーション、調節および抑制による腎障害の検出、予防および治療方法
JP6478908B2 (ja) 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
JP2007526455A (ja) 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
AU2007305166A1 (en) GRP78 as a predictor of responsiveness to therapeutic agents
JP7225115B2 (ja) リソソーム蓄積症およびリソソーム蓄積障害を処置するための組成物および方法
JP6764790B2 (ja) 視神経脊髄炎の治療に対する高可溶性アクアポリン−４細胞外ループペプチド免疫化
US20120058105A1 (en) Method of treatment of vascular complications
KR101667900B1 (ko) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용
JP2016196486A (ja) 脳腫瘍を治療するための分枝鎖アミノトランスフェラーゼ１（ｂｃａｔ１）の阻害剤
EP2904009B1 (de) Verbindungen zur behandlung der remyelinisierungsblockade von erkrankungen im zusammenhang mit der expression des herv-w-hüllproteins
Cai et al. Nanoparticle endothelial delivery of PGC-1α attenuates hypoxia-induced pulmonary hypertension by attenuating EndoMT-caused vascular wall remodeling
CN102713601A (zh) 体外筛选试验
Song et al. l‐Asparaginase‐mediated downregulation of c‐Myc promotes 1, 25 (OH) 2D3‐induced myeloid differentiation in acute myeloid leukemia cells
JP2009503493A (ja) 病理マーカーおよび治療標的としての、ｐｄｇｆ受容体に対する刺激性自己抗体
Ishizuka et al. Involvement of the receptor-associated prorenin system in the pathogenesis of human conjunctival lymphoma
WO2008156561A1 (en) Methods and compositions for the treatment and diagnosis of statin-induced myopathy
WO2019144971A1 (zh) Icam-1标记及其应用
US9644019B2 (en) Compounds for treating cardiac damage after ischaemia/reperfusion
WO2024024565A1 (ja) ニューロトリミンの機能阻害剤
US20240142457A1 (en) Use of casd1 as a biomarker of a cancer expressing the o-acetylated-gd2 ganglioside

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080814

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025